Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

Ruilope, 2010 - LCZ696 vs

KYOTO HEART Study, 2009 - valsartan vs non ARB strategy

Schmieder (vs HCTZ), 2009 - aliskiren vs hydrochlorothiazide

ALLAY, 2009 - aliskiren vs losartan

AVOID, 2008 - aliskiren vs placebo

HYVET, 2008 - indapamide vs placebo

ACCOMPLISH, 2008 - amlodipine plus benazepril vs hydrochlorothiazide plus benazepril

Andersen, 2008 - aliskiren vs ramipril

PROPHESS, 2008 - telmisartan vs placebo

ASCOT-BPLA, 2005 - amlodipine vs atenolol

ASCOT-BPLA, 2005 - atenolol vs amlodipine

VALUE, 2004 - valsartan vs amlodipine

SHELL, 2003 - lacidipine vs chlorthalidone

ANBP2, 2003 - enalapril vs diuretics

CONVINCE, 2003 - Atenolol or hydrochlorothiazide vs verapamil

SCOPE, 2003 - candesartan vs placebo

INVEST (Pepine), 2003 - verapamil vs atenolol

INVEST, 2003 - atenolol vs verapamil

CONVINCE, 2003 - verapamil vs diuretic or beta-blocker

ELSA, 2002 - atenolol vs lacidipine

LIFE, 2002 - losartan vs atenolol

ELSA, 2002 - lacidipine vs atenolol

LIFE, 2002 - atenolol vs Losartan

JMIC-B, 2002 - various ACEI vs nifedipine

ALLHAT (vs chlorthalidone), 2002 - lisinopril vs diuretics



See also:

  • All hypertension clinical trials
  • All clinical trials of anti hypertensive agent
  • All clinical trials of amlodipine
    		•  

    IDNT study, 2001

    Treatments

    Studied treatment Amlodipine 10mg/d
    Control treatment placebo

    Patients

    Patients hypertensive patients with nephropathy due to type 2 diabetes
    Inclusion criteria age between 30 and 70 years;type 2 diabetes mellitus; hypertension (systolic blood pressure of more than 135 mm Hg while sitting, a diastolic blood pressure of more than 85 mm Hg while sitting, or documented treatment with antihypertensive agents); proteinuria, with urinary protein excretion of at least 900 mg per 24 hours; serum creatinine between 1.0 and 3.0 mg per deciliter (88 and 265 �mol per liter) in women and 1.2 and 3.0 mg per deciliter (106 and 265 �mol per liter) in men.
    Baseline characteristics
    baseline BP 159/87 mmHg 
    Female (%) 32% 
    Age 58.6y 
    prior cardiovascular disease 29% 

    Method and design

    Randomized effectives 567 / 569 (studied vs. control)
    Design Parallel groups
    Blinding Double blind
    Follow-up duration 2�6
    Number of centre 210


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    83 / 567
         93 / 569
         0,90 [0,68;1,18]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 83 / 567 (14,6%) 93 / 569 (16,3%) 0,90 [0,68;1,18]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 14,64% 16,34% -17,1‰


    Reference(s)

    Trials register # NA
    • Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.. N Engl J Med 2001;345:851-60
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend